Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

Table 3 Changes in bead-like, intraretinal microvascular abnormality and fundus neovascularization, n (%)

	CDDP (n = 362)	Placebo (n = 121)	P value
Bead-like
Baseline			> 0.999
None	356 (98.34)	119 (98.35)
Present	6 (1.66)	2 (1.65)
12 weeks			> 0.999
None	356 (98.34)	119 (98.35)
Present	6 (1.66)	2 (1.65)
24 weeks			> 0.999
None	356 (98.34)	119 (98.35)
Present	6 (1.66)	2 (1.65)
Intraretinal microvascular abnormalities
Baseline			0.578
No abnormality	306 (84.53)	102 (84.30)
Mild abnormality	31 (8.56)	7 (5.79)
Severe abnormality	25 (6.91)	12 (9.92)
12 weeks			0.716
No abnormality	305 (84.25)	104 (85.96)
Mild abnormality	32 (8.84)	5 (4.13)
Severe abnormality	25 (6.91)	12 (9.92)
24 weeks			0.394
No abnormality	305 (84.25)	100 (82.64)
Mild abnormality	30 (8.29)	9 (7.44)
Severe abnormality	27 (7.46)	12 (9.92)
Fundus neovascularization
Baseline
None	362 (100)	121 (100)
Present	0 (0.00)	0 (0.00)
12 weeks			0.999
None	360 (99.45)	120 (99.17)
Present	2 (0.55)	1 (0.83)
24 weeks			0.999
None	360 (99.45)	120 (99.17)
Present	2 (0.55)	1 (0.83)

CDDP: Compound danshen dripping pill.